CDK8

Cyclin-dependent kinase 8

132,223 patent compounds predicted against CDK8, 75,412 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL91324	0.50	9/20
SCHEMBL84144	0.50	8/20
SCHEMBL153413	0.55	7/20
SCHEMBL13399	0.51	5/20
SCHEMBL164314	0.33	5/20
SCHEMBL162096	0.48	4/20
SCHEMBL163187	0.44	4/20
SCHEMBL161801	0.44	4/20
SCHEMBL160752	0.40	4/20
Abiraterone (SCHEMBL61108)	0.72	3/20
Abiraterone (SCHEMBL17816)	0.66	3/20
SCHEMBL101332	0.57	3/20
Inamrinone (SCHEMBL44012)	0.53	3/20
SCHEMBL158665	0.51	3/20
SCHEMBL163790	0.51	3/20
SCHEMBL158826	0.49	3/20
SCHEMBL163271	0.49	3/20
SCHEMBL162156	0.48	3/20
SCHEMBL164942	0.48	3/20
SCHEMBL117222	0.48	3/20

Germline variants in CDK8 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CDK8 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CDK8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
Adherence and Safety of Ribociclib Plus Aromatase Inhibitors in Patients With Early Stage, HR+ and HER2- Breast Cancer	PHASE4	NOT_YET_RECRUITING
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer	PHASE3	RECRUITING
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)	PHASE3	COMPLETED
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer	PHASE3	ACTIVE_NOT_RECRUITING
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients	PHASE3	RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6	PHASE2	RECRUITING
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors	PHASE1/PHASE2	COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy	PHASE2	COMPLETED
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC	PHASE2	ACTIVE_NOT_RECRUITING
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer	PHASE1/PHASE2	RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer	PHASE1/PHASE2	UNKNOWN
Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial	PHASE2	NOT_YET_RECRUITING
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.	PHASE1/PHASE2	COMPLETED
Palbociclib With Everolimus + Exemestane In BC	PHASE1/PHASE2	COMPLETED
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy	nan	COMPLETED
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer	nan	UNKNOWN
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period	nan	UNKNOWN
Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?	nan	UNKNOWN
Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.	nan	RECRUITING
Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CDK8 binder may also engage these)

Protein	Name	Similarity
Q8JH47	—	1.000	Q8JH47 →
Q8R3L8	—	1.000	Q8R3L8 →
Q6P3N6	—	1.000	Q6P3N6 →
CDK19	Cyclin-dependent kinase 19	0.993	landscape →
Q8BWD8	—	0.988	Q8BWD8 →
P49139	—	0.949	P49139 →
Q17IE8	—	0.947	Q17IE8 →
MAPKAPK2	MAP kinase-activated protein kinase 2	0.947	landscape →
Q9VT57	—	0.947	Q9VT57 →
DHX9	ATP-dependent RNA helicase A	0.944	landscape →
Q5R874	—	0.943	Q5R874 →
P49138	—	0.943	P49138 →
P49136	—	0.940	P49136 →
A5PKA5	—	0.937	A5PKA5 →
Q3UHD6	—	0.935	Q3UHD6 →
Q28141	—	0.935	Q28141 →
O70133	—	0.931	O70133 →
Q8K4V4	—	0.930	Q8K4V4 →
Q96L92	—	0.930	Q96L92 →
STK39	STE20/SPS1-related proline-alanine-rich protein kinase	0.929	landscape →
O54949	—	0.928	O54949 →
O88506	—	0.927	O88506 →
O54833	—	0.927	O54833 →
Q0GGW5	—	0.925	Q0GGW5 →
P17427	—	0.925	P17427 →
P18484	—	0.924	P18484 →
CTNNB1	Catenin beta-1	0.924	landscape →
Q9Z1W9	—	0.923	Q9Z1W9 →
B6V8E6	—	0.923	B6V8E6 →
A2A432	—	0.923	A2A432 →